Neuren Pharmaceuticals

Ultime notizie

Titoli nella lingua originale della fonte.

• Neuren Pharmaceuticals Limited (ASX:NEU): First Dividend Arrives as Phase 3 Investment Accelerates (si apre in una nuova scheda)

  Kalkine · 1 ott 2026

• What Will Its First European Launch Mean for Neuren (ASX:NEU)? (si apre in una nuova scheda)

  Kalkine Media · 30 set 2026

• Neuren Pharmaceuticals (ASX:NEU): How Could the New Trofinetide Patent Extend Protection? (si apre in una nuova scheda)

  Kalkine · 29 set 2026

• Neuren Pharmaceuticals (ASX:NEU): US Patent Allowance Supports Potential Trofinetide Protection Extension (si apre in una nuova scheda)

  Kalkine · 29 set 2026

• What lies ahead for Neuren (ASX:NEU) as FDA talks draw near? (si apre in una nuova scheda)

  Kalkine Media · 28 set 2026

• Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best? (si apre in una nuova scheda)

  The Motley Fool Australia · 21 set 2026

• What Could Neuren Pharmaceuticals (ASX:NEU) Mean for Midcaps? (si apre in una nuova scheda)

  Kalkine Media · 17 set 2026

• Sigma Healthcare, Neuren and Mesoblast: Financial Performance Across ASX Healthcare (si apre in una nuova scheda)

  Kalkine · 14 set 2026

• ASX Healthcare Stocks to Watch in September 2026: Sigma Healthcare (ASX:SIG), Neuren Pharmaceuticals (ASX:NEU) and Mesoblast (ASX:MSB) (si apre in una nuova scheda)

  Kalkine · 14 set 2026

• Neuren Pharmaceuticals (ASX:NEU): DAYBUE Royalties and NNZ-2591 Pipeline Define the Growth Story (si apre in una nuova scheda)

  Kalkine · 7 set 2026

• Neuren Pharmaceuticals (ASX:NEU) Up 1.51% — Royalties and NNZ-2591 Pipeline in the Spotlight (si apre in una nuova scheda)

  Kalkine · 4 set 2026